miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
Ann‐Kathrin Eisfeld, Clara D. Bloomfield(North Shore University Hospital), Heiko Becker(University of Freiburg), Jason H. Mendler(University of Rochester Medicine), Klaus H. Metzeler(University Hospital Leipzig), Meir Wetzler, Michael D. Radmacher, Ravi K. Patel(University of California, San Francisco), Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maria R. Baer(University of Maryland, Baltimore), Guido Marcucci(City of Hope), Albert de la Chapelle(Université Claude Bernard Lyon 1), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Thomas H. Carter(University of Iowa), Richard A. Larson(Urbana University), Sandya Liyanarachchi(The Ohio State University Wexner Medical Center), Joseph O. Moore(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krzysztof Mrózek(The Ohio State University), Deedra Nicolet(The Ohio State University), Stephan M. Tanner(Cancer Genetics (United States)), Bayard L. Powell(Atrium Health Wake Forest Baptist), Susan P. Whitman(The Ohio State University Wexner Medical Center), Sebastian Schwind, Yue-Zhong Wu(University of Iowa), Kati Maharry(Peter MacCallum Cancer Centre)
Cited by 69
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k